Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia

S Gillis; G Merin; D Zahger; M Deeb; B Drenger; E Hyam; A Eldor

doi:10.1046/j.1365-2141.1997.2633080.x

Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia

Br J Haematol. 1997 Sep;98(3):657-9. doi: 10.1046/j.1365-2141.1997.2633080.x.

Authors

S Gillis¹, G Merin, D Zahger, M Deeb, B Drenger, E Hyam, A Eldor

Affiliation

¹ Department of Haematology, Hadassah University Medical Centre, Ein Karem, Jerusalem, Israel.

PMID: 9332322
DOI: 10.1046/j.1365-2141.1997.2633080.x

Abstract

Anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia requires the use of other anticoagulants. We report a case in whom this was achieved using the heparinoid danaparoid (Orgaran). Based on our experience and a review of the literature, we provide guidelines for managing these rare patients. A danaparoid dose substantially lower than that recommended by the manufacturer may minimize bleeding complications.

Publication types

Case Reports

MeSH terms

Anticoagulants / adverse effects*
Cardiopulmonary Bypass*
Chondroitin Sulfates / therapeutic use*
Dermatan Sulfate / therapeutic use*
Drug Combinations
Heparin, Low-Molecular-Weight / adverse effects*
Heparitin Sulfate / therapeutic use*
Humans
Male
Middle Aged
Thrombocytopenia / chemically induced*

Substances

Anticoagulants
Drug Combinations
Heparin, Low-Molecular-Weight
Dermatan Sulfate
Chondroitin Sulfates
Heparitin Sulfate
danaparoid